Study #2016-0737
Phase II Randomized Clinical Trials Comparing Immunotherapy plus Stereotactic Ablative Radiotherapy (I-SABR) versus SABR Alone for Stage I, Selected Stage IIa or Isolated Lung Parenchymal Recurrent Non-small Cell Lung Cancer: I-SABR
MD Anderson Study Status
Not Accepting
Treatment Agent
Nivolumab
Description
This phase II trial studies how well stereotactic body radiation therapy with or without nivolumab works in treating patients with stage I-IIA non-small cell lung cancer or cancer that has come back. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving stereotactic body radiation therapy and nivolumab may work better at treating non-small cell lung cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lung Atypical Carcinoid Tumor, Lung Neuroendocrine Neoplasm, Lung Non-Small Cell Squamous Carcinoma, Minimally Invasive Lung Adenocarcinoma, Neuroendocrine Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Large Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC V8, Stage IA1 Lung Cancer AJCC V8, Stage IA2 Lung Cancer AJCC V8, Stage IA3 Lung Cancer AJCC V8, Stage IB Lung Cancer AJCC V8, Stage IIA Lung Cancer AJCC V8
Study phase:
Phase II
Physician name:
Joe Chang
Department:
Radiation Oncology
For general questions about clinical trials:
1-833-992-0260
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.